Controversial and open issues of diagnosis and treatment of myocarditis (based on the discussion of Russian national recommendations)
https://doi.org/10.15829/1560-4071-2021-4655
Abstract
In October 2020, the Russian Ministry of Health approved clinical guidelines for the management of patients with myocarditis. The aim of this review was to highlight controversial and open issues without unambiguous answer or those that were not described in the paper. The review highlights the objective factors that complicate the development of practical guidelines for the management of this category of patients. Comments on the definition and classification of inflammatory heart diseases are given. The approaches to the diagnosis of patients with suspected myocarditis are discussed. Particular attention is paid to the decision-making strategy in selecting optimal therapy in patients with documented myocarditis and the role of endomyocardial biopsy.
About the Authors
O. V. Blagova
I.M. Sechenov First Moscow State Medical University
Russian Federation
Competing Interests:
Russian Federation
Moscow.
Competing Interests:
No
O. M. Moiseeva
Almazov National Medical Research Center
Russian Federation
Competing Interests:
Russian Federation
St. Petersburg.
Competing Interests:
No
F. N. Paleev
National Medical Research Center of Cardiology
Russian Federation
Competing Interests:
Russian Federation
Moscow.
Competing Interests:
No
References
1. Caforio AL, Pankuweit S, Arbustini E, et al.; European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart J. 2013;34(33):2636-48, 2648a-2648d. doi:10.1093/eurheartj/eht210.
2. Pinto YM, Elliott PM, Arbustini E, et al. Proposal for a revised definition of dilated cardiomyopathy, hypokinetic non-dilated cardiomyopathy, and its implications for clinical practice: a position statement of the ESC working group on myocardial and pericardial diseases. Eur Heart J. 2016;37(23):1850-8. doi:10.1093/eurheartj/ehv727.
3. Seferovic PM, Tsutsui H, McNamara DM, et al. Heart Failure Association of the ESC, Heart Failure Society of America and Japanese Heart Failure Society Position statement on endomyocardial biopsy. Eur J Heart Fail. 2021;23(6):854-71. doi:10.1016/j.cardfail.2021.04.010.
4. Миокардиты. Клинические рекомендации Российского кардиологического общества, одобренные научно-практическим советом Минздрава РФ (16.10.2020г.). https://scardio.ru/content/Guidelines/2020/Clinic_rekom_Miokardit.pdf.
5. Kontorovich AR, Patel N, Moscati A, et al. Myopathic Cardiac Genotypes Increase Risk for Myocarditis. JACC Basic Transl Sci. 2021;6(7):584-92. doi:10.1016/j.jacbts.2021.06.001.
6. Goodwin JF. Clinical decisions in the management of the cardiomyopathies. Drugs. 1989;38(6):988-99. doi:10.2165/00003495-198938060-00009.
7. Ignatieva ES, Ryzhkova DV, Mitrofanova LB, Moiseeva OM. Magnetic resonance imaging of the heart in diagnostics of various types of myocarditis. Russian Journal of Cardiology. 2017;(2):30-8. (In Russ.) doi:10.15829/1560-4071-2017-2-30-38.
8. Ferreira VM, Schulz-Menger J, Holmvang G, et al. Cardiovascular Magnetic Resonance in Nonischemic Myocardial Inflammation: Expert Recommendations. J Am Coll Cardiol. 2018;72(24):3158-76. doi:10.1016/j.jacc.2018.09.072.
9. Paleev NR, Paleev FN. Non-coronary myocardial disease and its classification. Russian Journal of Cardiology. 2009;(3):5-9. (In Russ.) Палеев Н. Р., Палеев Ф. Н. Некоронарогенные заболевания миокарда и их классификация. Российский кардиологический журнал. 2009;(3):5-9.
10. Cooper LT, Baughman KL, Feldman AM, et al.; American Heart Association; American College of Cardiology; European Society of Cardiology; Heart Failure Society of America; Heart Failure Association of the European Society of Cardiology. The role of endomyocardial biopsy in the management of cardiovascular disease: a scientific statement from the American Heart Association, the American College of Cardiology, and the European Society of Cardiology. Endorsed by the Heart Failure Society of America and the Heart Failure Association of the European Society of Cardiology. J Am Coll Cardiol. 2007;50(19):1914-31. doi:10.1016/j.jacc.2007.09.008.
11. Charron P, Elliott PM, Gimeno JR, et al.; EORP Cardiomyopathy Registry Investigators. The Cardiomyopathy Registry of the EURObservational Research Programme of the European Society of Cardiology: baseline data and contemporary management of adult patients with cardiomyopathies. Eur Heart J. 2018;39(20):1784-93. doi:10.1093/eurheartj/ehx819.
12. Tschope C, Ammirati E, Bozkurt B, et al. Myocarditis and inflammatory cardiomyopathy: current evidence and future directions. Nat Rev Cardiol. 2021;18(3):169-93. doi:10.1038/s41569-020-00435-x.
13. Tschope C, Elsanhoury A, Schlieker S, et al. Immunosuppression in inflammatory cardiomyopathy and parvovirus B19 persistence. Eur J Heart Fail. 2019;21(11):1468-9. doi:10.1002/ejhf.1560.
14. Blagova OV, Nedostup AV, Sedov VP, et al. Effectiveness of myocarditis therapy depending on the diagnosis approach (with or without myocardial biopsy). Cardiovascular Therapy and Prevention. 2021;20(3):2637. (In Russ.) doi:10.15829/1728-8800-2021-2637.
15. Robinson J, Hartling L, Vandermeer B, et al. Intravenous immunoglobulin for presumed viral myocarditis in children and adults. Cochrane Database Syst Rev. 2020;8(8):CD004370. doi:10.1002/14651858.CD004370.
Review
For citations:
Blagova O.V., Moiseeva O.M., Paleev F.N. Controversial and open issues of diagnosis and treatment of myocarditis (based on the discussion of Russian national recommendations). Russian Journal of Cardiology. 2021;26(11):4655. https://doi.org/10.15829/1560-4071-2021-4655
Views:
802
Email this article 